Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Jairia Dela Cruz, 4 days ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
4 days ago
Use of thyroid hormone therapy does not seem to protect older adults with subclinical hypothyroidism against mortality, but it appears to confer survival benefits to those aged <65 years, results of a study have shown.

Experimental TYK2/JAK1 inhibitor shows promise against plaque psoriasis

27 Nov 2020

PF-06700841, a TYK2/JAK1* inhibitor under investigation, shows good efficacy against moderate-to-severe plaque psoriasis and carries a well-tolerable safety profile, according to new results of a phase IIa trial.

The study included 212 patients who were randomly assigned to receive the test drug at a 30-mg or 60-mg dose once-daily for the initial 4-week induction phase, followed by 8 weeks of 10 mg or 30 mg once daily, or 100 mg once weekly. Some patients were also randomized to take placebo for the entire duration of the study.

The primary study outcome was the 12-week change in the Psoriasis Area and Severity Index (PASI) score. Score reductions were apparent in all patients who had received the active treatment, and by week 12, all improvements were significantly different than in the placebo arm. A total of 164 patients were able to complete the study and were included in these outcome analyses.

Patients who received the 30-mg once-daily dose during the 4-week induction and 8-week maintenance phases showed the greatest mean 12-week change in PASI scores (least squares mean change, –17.3, 95 percent confidence interval [CI], –20.0 to –14.6).

The proportion of patients achieving 75-percent (PASI 75) and 90-percent (PASI 90) reduction in PASI scores relative to baseline were set as secondary outcomes. Both measures were higher across all active treatment groups relative to placebo. As with the primary outcome, patients taking the 30-mg once-daily dose throughout the 12-week period saw the best PASI75 and PASI 90.

In terms of safety, treatment-emergent adverse events (TEAEs) were reported in 136 patients across the seven active treatment groups, as opposed to only 13 in the placebo group. Forty-four episodes of TEAEs were deemed related to treatment, and nine patients had to discontinue treatment due to it; most of the treatment-related side effects were mild to moderate in severity and were resolved after discontinuation.

*Tyrosine kinase 2/Janus kinase 1

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Jairia Dela Cruz, 4 days ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
4 days ago
Use of thyroid hormone therapy does not seem to protect older adults with subclinical hypothyroidism against mortality, but it appears to confer survival benefits to those aged <65 years, results of a study have shown.